Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galena Biopharma GALE

Healthcare Biotechnology
"Galena Biopharma is a biopharmaceutical company. Its main activity is the development and commercialization of hematology and oncology therapies. Its pipeline includes products targeting hematology diseases, breast cancer, gastric cancer, and gynecological cancer. The company’s cancer immunotherapy consists of two areas: prevention of cancer reoccurrence and primary prevention of invasive... see more

Recent & Breaking News (NDAQ:GALE)

Galena Biopharma Provides 2015 Outlook

GlobeNewswire January 8, 2015

Galena Biopharma Provides 2015 Outlook

GlobeNewswire January 8, 2015

Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bond Oracle(TM) Results From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswire December 11, 2014

Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition

GlobeNewswire December 8, 2014

Galena Biopharma to Present HER2 Screening Data From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswire December 5, 2014

InMed Pharma's Hiring of Tiberend Highlights Biotech Focus

Accesswire December 3, 2014

Galena Biopharma Receives Notice of Allowance of U.S. Patent Application for GALE-401 (Anagrelide Controlled Release) Composition of Matter

GlobeNewswire December 2, 2014

Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition

GlobeNewswire December 1, 2014

Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference

GlobeNewswire November 25, 2014

Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC

GlobeNewswire November 20, 2014

Galena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial

GlobeNewswire November 18, 2014

Galena Biopharma to Present at the Stifel 2014 Healthcare Conference

GlobeNewswire November 13, 2014

Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients

GlobeNewswire November 11, 2014

Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase 2a Clinical Trial Data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting

GlobeNewswire November 7, 2014

Galena Biopharma to Present GALE-301 (Folate Binding Protein) Phase 2a Clinical Trial Data at the Society for the Immunotherapy of Cancer (SITC) 29th Annual Meeting on Friday, November 7, 2014

GlobeNewswire November 4, 2014

Galena Biopharma Reports Third Quarter 2014 Results

GlobeNewswire November 3, 2014

Heat Biologics Takes a New Approach to Immunotherapy

Accesswire November 3, 2014

The most undervalued, yet comprehensive cancer immunotherapy in development?

Accesswire November 3, 2014

Galena Biopharma to Report Third Quarter 2014 Financial Results on Monday, November 3, 2014

GlobeNewswire October 27, 2014

Galena Biopharma Receives Notice of Allowance of Improvement Patent for NeuVax(TM) (nelipepimut-S) in Japan

GlobeNewswire October 14, 2014